Superior Outcomes With Continuing Tenofovir Versus Switching to Zidovudine in Second-Line Antiretroviral Therapy in Haiti.

Samuel PierreIryna BocharovaCatherine NguyenFabienne HomeusGaetane JulmisteYoury MaciusVanessa RouzierPatrice SevereMarie Marcelle DeschampsColette Guiteau MoiseClovy BellotJohnny WuVanessa R RiveraRochelle SunJean W PapeBernard LiautaudSerena P Koenig

Published in: Open forum infectious diseases (2021)

We compared viral suppression rates between patients who continued tenofovir disoproxil fumarate (TDF)/lamivudine (3TC) vs switched to zidovudine (ZDV)/3TC in combination with a boosted protease inhibitor after failure of first-line efavirenz/TDF/3TC. We found higher rates of viral suppression with continued TDF/3TC compared with switching to ZDV/3TC.

Keyphrases

antiretroviral therapy
hiv infected patients
hiv infected
human immunodeficiency virus
hiv positive
hiv aids
sars cov
type diabetes
metabolic syndrome
weight loss
medical education